Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Boehringer Ingelheim
Express Scripts
McKinsey
McKesson

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

SARENIN Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Sarenin patents expire, and what generic alternatives are available?

Sarenin is a drug marketed by Procter And Gamble and is included in one NDA.

The generic ingredient in SARENIN is saralasin acetate. Additional details are available on the saralasin acetate profile page.

Summary for SARENIN
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 5
Patent Applications: 5
DailyMed Link:SARENIN at DailyMed
Drug patent expirations by year for SARENIN
Synonyms for SARENIN
(1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II
(Sar1,Val5,Ala8)Angiotensin II
[Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate
[Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate, >=97% (HPLC), powder
1-Sar-8-Ala Angiotensin II
1-Sarcosine-8-Alanine Angiotensin II
34273-10-4 (Parent)
39698-78-7
AC1L1WBL
Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-
CHEMBL1200670
CHEMBL356431
D04126
FO21Z580M4
GTPL598
L000747
LS-174459
N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine
NCGC00166135-01
P-113
P-113 Acetate
Sar-Arg-Val-Tyr-Val-His-Pro-Ala
Saralasin
Saralasin [INN:BAN]
Saralasin acetate
Saralasin acetate (USAN)
Saralasin acetate [USAN]
Saralasin Acetate, Hydrated
Saralasina [INN-Spanish]
Saralasine [INN-French]
Saralasinum [INN-Latin]
Sarenin (TN)
SCHEMBL2200145
UNII-FO21Z580M4

US Patents and Regulatory Information for SARENIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Procter And Gamble SARENIN saralasin acetate INJECTABLE;INJECTION 018009-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SARENIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Procter And Gamble SARENIN saralasin acetate INJECTABLE;INJECTION 018009-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Procter And Gamble SARENIN saralasin acetate INJECTABLE;INJECTION 018009-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
Colorcon
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.